Evidence map›Paper›PMID 41291120›Full record

ArticleScientific reports2025

Intravenous administration of CpG7909 lipoplex enhances anti-PD1 immunotherapy by modulating the tumor microenvironment and inducing durable tumor regression.

Chia-Mu Tu, Meng-Hsuan Lin, Chih-Peng Liu, Shih-Ta Chen, Chun-Min Liu, Meng-Ping She, Yu-Cheng Wang, Hsiang-Ching Wang, Yuan-Chia Chang, Li-Wen Chang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chia-Mu Tu *Industrial Development Graduate Program of CEB, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Meng-Hsuan Lin *Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Chih-Peng LiuBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Shih-Ta ChenBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Chun-Min LiuBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Meng-Ping SheBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Yu-Cheng WangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Hsiang-Ching WangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Yuan-Chia ChangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Li-Wen ChangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Yo-Wen LoBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Min-Xun LinBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Ping-Fu ChengBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Felice ChengBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
Jen-Kun ChenInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, Taiwan.
Jun-Lun MengInstitute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Ming-Hsi WuBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan. rexwu518@itri.org.tw.
Yu-Cheng SuDepartment of Biological Science and Technology, Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Room 720, BioICT Building, 75 Bo-Ai Street, Hsinchu, Taiwan. ycsu-johnny@nycu.edu.tw.

Funding

The Ministry of Economic Affairs, Taiwan MOEA111-EC-17-A-22-1651
6 · The paper itself

Abstract

The use of immune checkpoint inhibitors (ICIs) is a potential immunotherapy strategy to prevent immune escape in cancer cells. However, low immune infiltration and low antigen presentation in the tumor microenvironment (TME) have led to ineffective ICI immunotherapy in clinical studies. Although intratumoral injection of Toll-like receptor 9 (TLR9) agonists was shown to improve the efficacy of ICIs by increasing the number of tumor-infiltrating lymphocytes (TILs), it has limited effects on metastatic or deep-seated tumors. To overcome this challenge, we developed CpG7909 (a TLR9 agonist) lipoplex using a cationic lipid formulation, which exhibited preferential accumulation in tumors and spleen following systemic administration, Combination immunotherapy with an anti-PD1 antibody and CpG7909 lipoplex significantly promoted the infiltration of CD8

Indexed as

Immune Checkpoint InhibitorsImmunotherapyOligodeoxyribonucleotidesProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAdministration, IntravenousAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansLiposomesLung NeoplasmsLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CImmune Checkpoint InhibitorsLiposomesOligodeoxyribonucleotidesPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorToll-Like Receptor 9

Identifiers

PMID41291120
PMCPMC12749086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.